CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Ryan Vandrey

OPENALEX: A5004834451↗OPENALEX: A5121399847↗ORCID: 0000-0001-6657-884X↗

Affiliations

Organizations

Behavioral Pharma (United States)authorship · US Johns Hopkins Bayview Medical Centerauthorship · US Johns Hopkins Medicineauthorship · US Johns Hopkins Universityauthorship · US School of the Art Institute of Chicagoauthorship · US University of Vermontauthorship · US

Public evidence

17 connected articles

The acute and chronic pharmacokinetics and pharmacodynamics of oral cannabidiol with and without low doses of delta-9-tetrahydrocannabinol.2026 · Europe PMC Waldo: Automated discovery of adverse events from unstructured self reports.2025 · Europe PMC Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.2024 · Europe PMC Predictors of participant compliance with ecological momentary assessment among individuals with chronic pain who are using cannabis and opioids.2024 · Europe PMC Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples.2024 · Europe PMC Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain.2023 · Europe PMC The effects of oral and vaporized cannabis alone, and in combination with alcohol, on driving performance using the STISIM driving simulator: A two-part, double-blind, double-dummy, placebo-controlled, randomized crossover clinical laboratory protocol.2022 · PubMed Central Open Access Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores.2022 · Europe PMC Online survey of medicinal cannabis users: Qualitative analysis of patient-level data.2022 · Europe PMC Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.2022 · Europe PMC Refraining from use diminishes cannabis-associated epigenetic changes in human sperm.2021 · PubMed Central Open Access Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial.2021 · Europe PMC A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health.2021 · PubMed Central Open Access The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.2021 · PubMed Central Open Access Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.2019 · Europe PMC "Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.2018 · PubMed Central Open Access Training and Practices of Cannabis Dispensary Staff.2016 · Europe PMC

Registered research

Connected studies

Dose Ranging Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adultsnct07176208 Pilot Study Using Topical Cannabidiol (CBD) to Manage Osteoarthritic Knee Painnct07638189

Matched by exact identifiers only. Profile data: ORCID. Last retrieved 23/08/2026.

Ryan Vandrey - Medical Cannabis Research Engine